HRP20182088T1 - Režim doziranja za inhibitore janus kinaze (jak) - Google Patents

Režim doziranja za inhibitore janus kinaze (jak)

Info

Publication number
HRP20182088T1
HRP20182088T1 HRP20182088TT HRP20182088T HRP20182088T1 HR P20182088 T1 HRP20182088 T1 HR P20182088T1 HR P20182088T T HRP20182088T T HR P20182088TT HR P20182088 T HRP20182088 T HR P20182088T HR P20182088 T1 HRP20182088 T1 HR P20182088T1
Authority
HR
Croatia
Prior art keywords
strong
kinase inhibitors
janus kinase
dosage regime
regime
Prior art date
Application number
HRP20182088TT
Other languages
English (en)
Croatian (hr)
Inventor
Andrea J. GONZALES
Sallie B. COSGROVE
Phyllis B. MALPAS
Michael Rolf STEGEMANN
Wendy Turner COLLARD
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20182088(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of HRP20182088T1 publication Critical patent/HRP20182088T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP20182088TT 2012-07-20 2013-07-18 Režim doziranja za inhibitore janus kinaze (jak) HRP20182088T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
EP13742573.2A EP2874630B1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
HRP20182088T1 true HRP20182088T1 (hr) 2019-02-08

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182088TT HRP20182088T1 (hr) 2012-07-20 2013-07-18 Režim doziranja za inhibitore janus kinaze (jak)

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20150028299A (enExample)
CN (2) CN108354938A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2958921T1 (sl) 2013-02-22 2017-12-29 Pfizer Inc. Derivati pirolo(2,3-d)pirimidina kot inhibitorji Janus kinaz (JAK)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
FI3915989T3 (fi) * 2019-01-30 2023-09-20 Felicamed Biotechnology Co Ltd Jak:n estäjä ja sen valmistusmenetelmä
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
US11827657B2 (en) 2020-12-18 2023-11-28 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
US20240300943A1 (en) * 2021-03-16 2024-09-12 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
WO2022222948A1 (zh) * 2021-04-22 2022-10-27 深圳微芯生物科技股份有限公司 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916833T2 (de) * 1998-06-19 2005-04-14 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-verbindungen
ES2467109T3 (es) 2008-08-20 2014-06-11 Zoetis Llc Compuestos de pirrolo[2,3-d]pirimidina

Also Published As

Publication number Publication date
JP2017019816A (ja) 2017-01-26
CN108354938A (zh) 2018-08-03
LT2874630T (lt) 2019-02-11
JP2015522620A (ja) 2015-08-06
DK2874630T3 (en) 2019-01-28
ES2707627T3 (es) 2019-04-04
CN104470525A (zh) 2015-03-25
KR20150028299A (ko) 2015-03-13
AU2013292547B2 (en) 2017-05-04
CA2878867C (en) 2018-01-09
CY1121436T1 (el) 2020-05-29
HK1252083A1 (zh) 2019-05-17
IN2015DN00370A (enExample) 2015-06-12
SMT201900044T1 (it) 2019-02-28
MX2015000871A (es) 2015-05-07
EP2874630A1 (en) 2015-05-27
JP6022063B2 (ja) 2016-11-09
RS58242B1 (sr) 2019-03-29
WO2014015107A1 (en) 2014-01-23
ZA201500134B (en) 2016-08-31
AU2013292547A1 (en) 2015-01-22
PT2874630T (pt) 2019-01-31
KR20170034949A (ko) 2017-03-29
HK1209314A1 (en) 2016-04-01
MX360857B (es) 2018-11-20
HUE042771T2 (hu) 2019-07-29
BR112015000808A2 (pt) 2017-06-27
CA2878867A1 (en) 2014-01-23
US20150126535A1 (en) 2015-05-07
NZ703152A (en) 2016-03-31
PL2874630T3 (pl) 2019-04-30
SI2874630T1 (sl) 2019-04-30
US9522151B2 (en) 2016-12-20
EP2874630B1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
HRP20182088T1 (hr) Režim doziranja za inhibitore janus kinaze (jak)
IL265007B (en) Pyrazolopyrimidine compounds as kinase inhibitors
DK2710007T3 (da) Kinasehæmmere
CO6970602A2 (es) Inhibidores de quinasa
DK2903618T3 (da) Rho-kinase-inhibitorer
DK3321262T3 (da) Serin-/threoninkinasehæmmere
BR112014000653A2 (pt) inibidores de tirosina quinase de bruton
BR112013029620A2 (pt) inibidores de tirosina quinase de bruton
ME03610B (me) Naftiridinska jedinjenja kao inhibitori jak kinaze
IL230561A0 (en) Inhibitors of bruton's tyrosine kinsae
IL228108A0 (en) Triazolopyridine compounds as pim kinase inhibitors
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
DK2917210T3 (da) Alk kinase-inhibitorer
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
EP2916836A4 (en) AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE (SYK) INHIBITOR
PL2634185T3 (pl) Inhibitory kinazy TYK2
CO6990735A2 (es) Inhibidores de pirazina cinasa
BR112014033056A2 (pt) inibidores da proteína quinase
BR112014029718A2 (pt) inibidores da proteína quinase
PL3030561T3 (pl) N-cyjanometyloamidy jako inhibitory kinaz janusowych